NCT04398368 - Gemcitabine for the Prevention of Intravesical Recurrence of Urothelial Cancer in Patients With Upper Urinary Tract Urothelial Cancer Undergoing Radical Nephroureterectomy, GEMINI Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 5, 2020

Primary Completion Date

February 2, 2023

Study Completion Date

February 2, 2023

Conditions

Stage 0a Renal Pelvis and Ureter Cancer AJCC v8Stage 0a Renal Pelvis Cancer AJCC v8Stage 0a Ureter Cancer AJCC v8Stage 0is Renal Pelvis and Ureter Cancer AJCC v8Stage 0is Renal Pelvis Cancer AJCC v8Stage 0is Ureter Cancer AJCC v8Stage I Renal Pelvis and Ureter Cancer AJCC v8Stage I Renal Pelvis Cancer AJCC v8Stage I Ureter Cancer AJCC v8Stage II Renal Pelvis and Ureter Cancer AJCC v8Stage II Renal Pelvis Cancer AJCC v8Stage II Ureter Cancer AJCC v8Stage III Renal Pelvis and Ureter Cancer AJCC v8Stage III Renal Pelvis Cancer AJCC v8Stage III Ureter Cancer AJCC v8Stage IV Renal Pelvis and Ureter Cancer AJCC v8Stage IV Renal Pelvis Cancer AJCC v8Stage IV Ureter Cancer AJCC v8

Interventions

DRUG

Gemcitabine Hydrochloride

Given intravesically

Trial Locations (4)

15232

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh

27157

Wake Forest Baptist Medical Center, Winston-Salem

55905

Mayo Clinic in Rochester, Rochester

32224-9980

Mayo Clinic in Florida, Jacksonville